Top 22 Companies in Global Fungal Infection Diagnosis Market 2025: Strategic Overview and Future Trends (2024–2035)
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The global fungal infection diagnosis market refers to the medical, lab-based, and molecular techniques that help identify and measure the extent of fungal infections. The techniques play an important role in the management of such infections and have been helpful in lowering mortality rates through appropriate therapeutic interventions. The applications of the market include molecular diagnostics, MALDI-TOF, biomarkers for serological tests, and imaging technologies. All these applications are useful in the rapid and accurate detection of fungal infections.
According to the Centers for Disease Control and Prevention (CDC), fungal diseases account for approximately 13 million outpatient visits and over 130,000 hospitalizations annually in the U.S., underscoring significant diagnostic demand and supporting growth in the global fungal infection diagnosis market.
The global market for fungal infection diagnosis is also showing signs of innovation in multiplex PCR technology, NGS technology, and AI-based diagnostics. Future opportunities in this market include point-of-care diagnostics, drug resistance detection, digital health, and biomarker-based personalized medicine, which are likely to improve accessibility, therapeutic outcomes, and operational efficiency in healthcare delivery.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Fungal Infection Diagnosis Market & Statistics
- The Market Size for Fungal Infection Diagnosis Market Was Estimated to be worth USD 271.4 million in 2024.
- The Market Size is Going to Expand at a CAGR of 7.01% between 2025 and 2035.
- The Global Fungal Infection Diagnosis Market Size is anticipated to reach USD 4.36 billion by 2035.
- North America is estimated to generate the highest demand during the forecast period in the Global Fungal Infection Diagnosis Market.
- Asia Pacific is projected to grow the fastest during the forecast period in The Global Fungal Infection Diagnosis Market.
Market Segmentation
Global Fungal Infection Diagnosis Market Size, Share, By Type (Cryptococcosis, Candidiasis, Dermatophytosis, Aspergillosis, and Others), By Treatment (Intravenous Treatment, Oral Treatment, and Topical Treatment), By Route of Administration (Intravenous, Topical, and Oral), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035
Regional growth and demand
Asia‑Pacific is expected to grow the fastest during the forecast period in the fungal infection diagnosis market. It is because of high disease burden and increasing healthcare investment. A strong demand is driven by high-risk populations such as the elderly and the increasing rate of immunocompromised populations in emerging markets such as China and India. From an economic perspective, increased investment in infrastructure and the use of advanced molecular diagnostics seek to counteract the high productivity losses estimated to reach trillions of dollars due to antimicrobial resistance.
North America is anticipated to generate the highest demand during the forecast period in the fungal infection diagnosis market. It is due to advanced healthcare facilities, high diagnostic awareness, and considerable healthcare spending. It has access to the early adoption of advanced and novel diagnostic techniques, the presence of major companies, and favourable reimbursement policies. Furthermore, the growing rate of immunocompromised diseases and hospital-acquired infections will also fuel the market, thereby maintaining its position as a dominant force over the projected period.
Ready to lead the Fungal Infection Diagnosis Market?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 trends in the fungal infection diagnosis market
- Molecular Diagnostics Dominance
- Rapid Point-of-Care (POC) Testing
- Next-Generation Sequencing
- Biomarker-Based Diagnostics
- Drug Resistance Testing
- Artificial Intelligence (AI) and Digital Imaging
- Expanding Testing for Immunocompromised Populations
- Non-Invasive Sampling Techniques
- Detection of Novel/Emerging Fungal Pathogens
- Microfluidic Chip Technology
- Molecular Diagnostics Dominance
PCR-based assays are becoming more widely used to identify pathogens at the genus, species, and strain levels quickly and accurately, decreasing the need for laborious culture techniques.
- Rapid Point-of-Care (POC) Testing
The creation of lateral flow devices (LFDs) is essential for the timely identification of invasive infections such as aspergillosis.
- Next-Generation Sequencing
Metagenomic NGS is used to better discover rare fungi by directly identifying complex or unknown fungal infections from clinical samples.
- Biomarker-Based Diagnostics
A greater dependence on serum indicators such as galactomannan and D-glucan for early aspergillosis and invasive candidiasis detection.
- Drug Resistance Testing
To inform treatment choices, there is a strong emphasis on identifying multidrug-resistant Candida auris and azole-resistant Aspergillus.
Top 22 Companies Leading the fungal infection diagnosis market
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Siemens Healthineers
- F. Hoffmann-La Roche Ltd.
- bioMérieux SA
- Bruker Corporation
- Danaher Corporation (Beckman Coulter)
- Merck KGaA
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories Inc.
- PerkinElmer Inc.
- T2 Biosystems Inc.
- Luminex Corporation (now part of DiaSorin)
- QuidelOrtho Corporation
- IMMY Inc.
- Myconostica Ltd. (Lab21)
- Hain Lifescience GmbH
- Associates of Cape Cod, Inc.
- Fujifilm Holdings Corporation
- Era Biology Group
- Dynamiker Biotechnology (Tianjin) Co., Ltd.
- Zhanjiang A & C Biological Ltd.
- Abbott Laboratories
Headquarters: Abbott Park, Illinois, U.S.
The Abbott Laboratories is founded in 1888 and currently has 114,000 to 115,000 employees worldwide. The revenue generated is close to 44.3 USD billion in 2025. Abbott Laboratories has advanced diagnostic assays and testing platforms that are widely used in the diagnosis of fungal infections. Abbott Laboratories is competing well in the global market of fungal infection diagnosis.
2. Thermo Fisher Scientific Inc.
Headquarters: Waltham, Massachusetts, U.S.
The company, Thermo Fisher Scientific Inc. Was founded in 1956 and currently has around 125,000 employees. The company reported revenue of around 44.56 billion USD in 2025. The company’s product portfolio comprises sophisticated molecular diagnostic test kits, PCR-based products, immunoassays, and specialty diagnostic products used in the detection of fungal infections, thus enhancing the competitive advantage and growth of the company in the fungal infection detection market.
3. Siemens Healthineers
Headquarters: Erlangen, Germany
The Siemens Healthineers, which was formed as a spin-off of Siemens AG in 2017 and has a workforce of approximately 74,000 employees worldwide, reported a revenue of approximately €23.4 billion for the financial year 2025. It offers cutting-edge solutions for laboratory diagnostics, molecular diagnostics, and imaging-integrated diagnostics, which helps to accurately identify fungal infections and further consolidates its position of innovation-driven leadership in the global fungal infection diagnosis market.
4. F. Hoffmann-La Roche Ltd.
Headquarters: Basel, Switzerland
The F. Hoffmann-La Roche Ltd., company was founded in 1896 and has around 103,000 employees worldwide. The company made around CHF 60-65 billion USD 65-70 billion in revenue in 2025. The company offers high-end in vitro diagnostics, molecular diagnostics, and immunoassay technology used in detecting fungal infections, thus emphasizing its position as a market innovator and having strong competitiveness in the global market for diagnosing fungal infections.
5. bioMérieux SA
Headquarters: Marcy-l'Étoile, France
The bioMérieux SA, founded in 1963, is a company that has approximately 13,500 employees worldwide. The revenue generated by the company is approximately 3.9 to 4.0 billion euros in 2025. The company provides a wide range of products such as microbiology testing systems, molecular diagnostics, immunoassay, and culture-based solutions that are useful in fungal infection diagnosis.
Are you ready to discover more about the fungal infection diagnosis market?
The report provides an in-depth analysis of the leading companies operating in the global fungal infection diagnosis market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Abbott Laboratories
- Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Thermo Fisher Scientific Inc.
- Siemens Healthineers
- F. Hoffmann-La Roche Ltd.
- bioMérieux SA
- Bruker Corporation
- Danaher Corporation (Beckman Coulter)
- Merck KGaA
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories Inc.
- PerkinElmer Inc.
- T2 Biosystems Inc.
- Luminex Corporation (now part of DiaSorin)
- QuidelOrtho Corporation
- IMMY Inc.
- Myconostica Ltd. (Lab21)
- Hain Lifescience GmbH
- Associates of Cape Cod, Inc.
- Fujifilm Holdings Corporation
- Era Biology Group
- Dynamiker Biotechnology (Tianjin) Co., Ltd.
- Zhanjiang A & C Biological Ltd.
- Others.
Conclusion
The global fungal infection diagnosis market is expected to experience significant growth and is anticipated to rise from around 2.07 billion USD in 2024 to 4.36 billion USD in 2035, reflecting a compound annual growth rate of 7.01% between 2025 and 2035. The market is mainly influenced by the growing incidence of invasive fungal infections, the rise in immunocompromised populations, and the rise in healthcare investments. The market is also being driven by advances in technology, which are improving the accuracy and time-to-result of diagnosis techniques like molecular diagnostics, NGS, and AI-based systems. The North American market is the most dominant due to the strong infrastructure and healthcare investments in the region, followed by the Asia-Pacific market, which is expected to be the fastest-growing due to the need for new clinical opportunities and infrastructure development in the region. The market is expected to be influenced by the growing need for point-of-care testing, drug resistance testing, and personalized medicine, which is expected to change the competitive dynamics of the market in the coming years, reflecting a strong and steady growth pattern in the market and strong opportunities for innovation-led market penetration and strategic expansion for the key players in the market.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?